Entera Bio Ltd. — Director's Dealing 2026

Jan 2, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2026-01-01

Reporting Person: LIEBERMAN GERALD M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-01	Ordinary Shares, par value NIS 0.0000769 per share	A	38294	—	Acquired	338454	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-01	Stock Option (right to buy)	$1.94	A	33505	Acquired	2036-01-01	Ordinary Shares, par value NIS 0.0000769 per share (33505)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares, par value NIS 0.0000769 per share	6200	Indirect
Ordinary Shares, par value NIS 0.0000769 per share	6200	Indirect
Ordinary Shares, par value NIS 0.0000769 per share	6200	Indirect
Ordinary Shares, par value NIS 0.0000769 per share	6200	Indirect

Footnotes

F1: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.

F2: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.